BB Biotech swings to H1 FY26 net profit of CHF 429.79 million; NAV rises 16.4% YTD to CHF 55.95 per share

• BB Biotech swung to a H1 profit of CHF 429.79 million, reversing a CHF 341.17 million loss a year earlier; EPS turned to CHF 7.79.
• NAV rose 16.4% year-to-date in CHF, while the share price gained 14.1% over the same period.
• Q2 net profit turned to CHF 451.17 million from a loss of CHF 100.24 million; NAV climbed 17.2% in CHF.
• Portfolio expanded with 12 new positions; the firm ended June with 37 listed holdings and 39 total investments.
• Board updated the dividend framework for FY2026, targeting a 3%-5% yield based on a 20-day VWAP in late January/early February.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BB Biotech AG published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.